CDKN2A and cancer: Future studies will determine the extent to which organ-specific effects apply to other common cancer drivers, many of which also enhance metastatic proclivity; such drivers include missense mutations of the TP53 tumor suppressor gene51, gains or amplifications at the mutant KRAS22,52 and MYC53 loci or deletions at the CDKN2A locus21.